Safety, tolerability, pharmacokinetics, and immunological activity ...

Sobieszczyk, Magdalena E.; Mannheimer, Sharon B.; Paez, Carmen A.; Yu, Chenchen; Gamble, Theresa; Theodore, Deborah Anne; Chege, Wairimu; Yacovone, Margaret; Hanscom, Brett; Heptinstall, Jack; Seaton, Kelly E.; Zhang, Lily; Miner, Maurine D.; Eaton, Amanda; Weiner, Joshua A.; Kalams, Spyros; Stephenson, Kathryn; Julg, Boris; Caskey, Marina; Nussenzweig, Michel; Gama, Lucio; Barouch, Dan H.; Ackerman, Margaret E.; Tomaras, Georgia D.; Montefiori, David; HVTN 130 HPTN 089 Study Team

This phase 1 study showed the feasibility of combining anti-HIV bnAbs targeting different sites on the HIV envelope in people living without HIV. It also showed that the dual-antibody and triple-antibody combinations were as effective as the individual antibodies at neutralisation, thus justifying a combination approach going forward for additional monoclonal antibody studies for HIV prevention. The fact that modelling predicted the combination neutralisation titre on the basis of the single antibody titres will be valuable for future trial design of different antibody combinations.


  • thumnail for Lancet HIV mAb pub 2023.docx Lancet HIV mAb pub 2023.docx application/vnd.openxmlformats-officedocument.wordprocessingml.document 14.1 KB Download File
  • thumnail for Lancet HIV mAb manuscript 1-s2.0-S2352301823001406-main.pdf Lancet HIV mAb manuscript 1-s2.0-S2352301823001406-main.pdf application/pdf 262 KB Download File

Also Published In

More About This Work

Academic Units
Published Here
November 3, 2023